Moreover, the DAPA-CKD trial was the first kidney outcome study to evaluate the effects of the SGLT2 inhibitors on patients with CKD with and without T2D (patients with diabetes, 68%; patients without diabetes, 32%) [16]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.